Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Jinxin Technology Holding Company American Depositary Shares (NAMI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: NAMI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 259.37M USD | Price to earnings Ratio 28.93 | 1Y Target Price - |
Price to earnings Ratio 28.93 | 1Y Target Price - | ||
Volume (30-day avg) 132322 | Beta - | 52 Weeks Range 2.25 - 7.75 | Updated Date 02/17/2025 |
52 Weeks Range 2.25 - 7.75 | Updated Date 02/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 16.54% | Operating Margin (TTM) 16.15% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 28.93 | Forward PE - | Enterprise Value 245746076 | Price to Sales(TTM) 0.64 |
Enterprise Value 245746076 | Price to Sales(TTM) 0.64 | ||
Enterprise Value to Revenue 4.4 | Enterprise Value to EBITDA 18.23 | Shares Outstanding 64041200 | Shares Floating 37072526 |
Shares Outstanding 64041200 | Shares Floating 37072526 | ||
Percent Insiders - | Percent Institutions 0.03 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jinxin Technology Holding Company American Depositary Shares
Company Overview
History and Background
Jinxin Technology Holding Company Limited is a leading enterprise in assisted reproductive technology (ART) services in China. Founded in 2009, Jinxin has grown through strategic acquisitions and organic growth, focusing on providing comprehensive ART services and building a leading brand in the reproductive health sector.
Core Business Areas
- ART Services: Provides comprehensive ART services, including IVF, egg freezing, and other related treatments.
- Management Services: Offers management services to clinics, including operational support and strategic consulting.
- Ancillary Services: Provides related ancillary services such as genetic testing and pre-pregnancy consultation.
Leadership and Structure
The company is led by a team of experienced executives in the healthcare and technology sectors. The organizational structure includes business units focused on ART services, clinic management, and support functions.
Top Products and Market Share
Key Offerings
- In-Vitro Fertilization (IVF): IVF is a core service offered by Jinxin. Jinxin is estimated to have a 3.3% market share in China. Key competitors include other private and public ART clinics. The total revenue for the IVF business is not publicly broken down by product.
- Intracytoplasmic Sperm Injection (ICSI): ICSI is a specialized IVF procedure. Market share data specific to ICSI is not publicly available. Competitors are similar to IVF, consisting of public and private ART clinics.
- Egg Freezing: Egg freezing is an increasingly popular option for women. Market share data for this product is not publicly broken down for Jinxin. Competitors include other ART clinics providing egg-freezing services.
Market Dynamics
Industry Overview
The ART market in China is experiencing significant growth, driven by increasing infertility rates, rising disposable incomes, and government support for ART services. The market is fragmented, with both public and private players.
Positioning
Jinxin positions itself as a leading private ART service provider in China, with a focus on quality, advanced technology, and patient-centric care. Its competitive advantages include its established brand reputation, extensive network of clinics, and experienced medical team.
Total Addressable Market (TAM)
The TAM for ART services in China is estimated to be in the billions of dollars. Jinxin, with its current market share, has significant potential to expand its reach within this TAM.
Upturn SWOT Analysis
Strengths
- Leading ART service provider in China
- Strong brand reputation
- Extensive network of clinics
- Experienced medical team
- Advanced technology and equipment
Weaknesses
- Geographic concentration of clinics
- High operating costs
- Reliance on key medical personnel
Opportunities
- Expanding into new geographic regions
- Increasing market penetration
- Offering new services, such as genetic testing
- Acquiring smaller ART clinics
Threats
- Intense competition from other ART clinics
- Changes in government regulations
- Economic slowdown
- High staff attrition rate
Competitors and Market Share
Key Competitors
- PKX (Peking University Healthcare)
- HSTO (Hygeia Healthcare)
Competitive Landscape
Jinxin's advantages include its leading market position and strong brand, while its disadvantages include its limited geographic presence compared to some larger competitors.
Major Acquisitions
Hangzhou BoAi Hospital
- Year: 2016
- Acquisition Price (USD millions): 130
- Strategic Rationale: Expanded Jinxin's presence in the Zhejiang province and added capacity for ART services.
Shenzhen Zhongshan Hospital
- Year: 2016
- Acquisition Price (USD millions): 154
- Strategic Rationale: Strengthened Jinxin's position in the Shenzhen area and enhanced its ART service offerings.
Growth Trajectory and Initiatives
Historical Growth: Jinxin has demonstrated growth through acquisitions and organic expansion of its clinic network.
Future Projections: Analyst estimates for future growth are available from financial analysts covering the stock.
Recent Initiatives: Jinxin has focused on expanding its service offerings, improving patient care, and strengthening its brand reputation.
Summary
Jinxin Technology is a leading ART service provider in China with a strong brand and extensive clinic network. Its strengths lie in its reputation and technology, but it faces challenges in geographic concentration and intense competition. The company has opportunities for expansion but must mitigate regulatory and economic risks to sustain growth. Jinxin is a promising company in the ART market.
Similar Companies
HSTO
Histogen Inc
HSTO
Histogen Inc
PKX
POSCO Holdings Inc
PKX
POSCO Holdings Inc
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- Financial News Providers (e.g., Bloomberg, Reuters, Yahoo Finance)
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may vary. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jinxin Technology Holding Company American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-12-06 | Founder, Chairman of the Board of Directors & CEO Mr. Jin Xu | ||
Sector Communication Services | Industry Internet Content & Information | Full time employees 93 | Website https://www.namibox.com |
Full time employees 93 | Website https://www.namibox.com | ||
Jinxin Technology Holding Company operates as a digital content service provider that creates and develops digital self-learning contents and leisure reading materials in the People's Republic of China. The company offers digital version of mainstream textbooks used in primary schools and middle schools; and digital textbooks in Chinese and English subjects used in K-9 schools. It distributes digital and integrated educational contents primarily through Namibox, a learning app; telecom and broadcast operators; and third-party devices. Jinxin Technology Holding Company was founded in 2014 and is based in Shanghai, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.